Wolowacz S, Lloyd A, Doward L, Hawe E. Estimating health-state utility for economic models in clinical trials and real-world studies. Presented at the ISPOR 2024; May 5, 2024. Atlanta, GA.
Doward L, Hawe E, Lloyd A, Wolowacz S. Estimating health-state utility for economic models in clinical trials and real-world studies. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark.
Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP. Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.
Wolowacz S. Incorporating informal care considerations in HTA. Presented at the ISPOR Europe 2022; November 7, 2022.
Brazier JE, Knight H, Wolowacz SE. Including caregiver / family member quality of life in economic evaluations – your questions answered. Presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark.
Wolowacz SE, Benedict A, Kamal K. Improving the availability and quality of utility estimates for the post-progression period in oncology models: recommendations based on a systematic review. Presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.
Wolowacz SE, Briggs A, Doward L, Lloyd A. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2018 ISPOR 21st Annual European Congress; November 10, 2018. Barcelona, Spain.
Wolowacz S, Briggs A, Lloyd A, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 20th Annual European Congress; November 4, 2017. Glasgow, Scotland. Previously presented at the ISPOR 19th Annual European Congress.
Muszbek N, Benedict A, Wolowacz S. Health economic modeling in oncology. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.
Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.
Boysen M, Tyas D, Ling C, Wolowacz S. The new NICE cancer drugs fund technology appraisal process: your questions answered. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.
Muszbek N, Wolowacz S, Benedict A. Health economic modeling in oncology. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.
Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2016 ISPOR 19th Annual European Congress; October 29, 2016. Vienna, Austria.
Earnshaw S, Brogan A, Wolowacz S. Budget impact analysis II: applications & design issues. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. Previously presented at the ISPOR 20th Annual International Meeting.
Wolowacz S, Briggs A, Doward L. Measurement of health state utility values for economic models in clinical studies – findings of the good practices task force. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Earnshaw SR, Brogan AJ, Wolowacz SE. Budget impact analysis II: applications and design issues. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Muszbek N, Wolowacz S, Benedict A. Modeling in oncology: the taming of the shrews? Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Wolowacz SE, Briggs A, Lloyd A, Belozeroff V, Clarke P, Goeree R, Doward LC, Petrillo J. Health state utility values: measuring, modelling, and mapping. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.
Earnshaw SR, Mullins CD, Brogan AJ, Wolowacz SE. Budget impact analysis: applications and design issues. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. Previously presented at the 2014 ISPOR 19th Annual International Meeting.
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring utility for economic models within clinical trials: can we do better? Presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Longson C, Wolowacz SE, Sculpher MJ, Khan SB. The National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: an update on the first round of submission. Presented at the 2006 ISPOR 11th Annual International Meeting; May 2006. Philadelphia, PA.
Doyle V, Pearson R, Wolowacz SE, McTaggart S. An investigation of the growth of human dermal fibroblasts on poly-l-lactic acid in vitro. Presented at the European Society for Biomaterials Meeting; 1995. Porto, Portugal.